intrahepatic cholangiocarcinoma

CT scan

18F-FDG PET/CT Radiomic Features Help Classify Intrahepatic Cholangiocarcinoma

A new study has demonstrated the ability of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to classify intrahepatic cholangiocarcinoma (ICC) and predict microvascular invasion. The study, published in Quantitative Imaging in Medicine and Surgery, offers a potential noninvasive biomarker for individualized treatment decisions in patients with primary liver cancers. “Positron emission tomography/computed tomography (PET/CT)-based radiomics…

Cancer cells

SOX9-AS1 Drives Tumor Growth in iCCA Study

Dysregulated patterns of long noncoding RNAs (lncRNAs), such as SOX9-AS1, may have both diagnostic and prognostic values in intrahepatic cholangiocarcinoma (iCCA), according to a recently published study in Clinics and Research in Hepatology and Gastroenterology. Currently, surgical resection is the therapy of choice for patients with iCCA; however, due to the vagueness and late appearance of symptoms, as…

operating room

New Model Estimates Survival After Curative-Intent Resection in iCCA

Researchers developed a new prognostic model that is able to measure the effect of tumor- and patient-specific factors on overall survival in intrahepatic cholangiocarcinoma (iCCA) following surgery.  “The proposed dynamic model . . . performed well at internal validation and could assist both patients and providers in predicting prognosis and in tailoring treatment and follow-up…

Stem Cell Research Pipette

Four Genes Linked With iCCA Effective in Predicting Prognosis

Innovative use of genes as biomarkers for intrahepatic cholangiocarcinoma (iCCA) could determine response to chemotherapy, according to an article recently published in Stem Cell Research & Therapy. “We discovered that 4-key-genes are associated with self-renewal ability of [iCCA] and their overexpression could enhance chemoresistance of cholangiocarcinoma cells,” the authors wrote. This experimental research found that…

carcinoma cell

Brusatol Promotes Apoptosis in iCCA Oncocytes

Brusatol can inhibit proliferation and suppress the epithelial-mesenchymal transition process in intrahepatic cholangiocarcinoma (iCCA) oncocytes, according to a new study published in Phytomedicine. Researchers obtained the results in iCCA cell function experiments followed by verification in a mouse model. “Brusatol is a quassinoid extracted from the seeds of Brucea sumatrana and has been developed as…

cell research

SUOX and GLUT1 Expression as Prognostic Factors in iCCA

Sulfite oxidase (SUOX) and glucose transporter 1 (GLUT1) expression both have been shown to be independent prognostic factors in patients with large duct type intrahepatic cholangiocarcinoma (iCCA), with no correlation demonstrated between the 2 biomarkers, according to a new study published in Human Pathology. A clinicopathologic study was conducted among 96 consecutive patients who had been…

infusion bottle

Drug-Eluting Beads With Systemic Therapy Shows Promise for CCA

The concomitant use of drug-eluting bead, irinotecan therapy (DEBIRI), and chemotherapy with gemcitabine/cisplatin may increase survival in patients with unresectable intrahepatic cholangiocarcinoma (CCA), according to results of a multicenter, randomized phase 2 clinical trial. Although the preferred approach to CCA is surgical resection, most patients are not eligible for surgery due to advanced disease progression.…

Biliary Surgery, SMAD4, and PBRM1 Predict Metastasis Risk in CCA

Mutations in SMAD4 and PBRM1 as well as a history of biliary surgery are all independent protective factors for metastasis in advanced cholangiocarcinoma (CCA), according to a new study published in the Journal of International Medical Research. The researchers also found that TP53 mutations were significantly more frequent in extrahepatic CCA and that mutations in…

platelet

Mean Platelet Volume as a New Marker to Distinguish iCCA From HCC

Researchers discovered that mean platelet volume (MPV) is an independent factor in helping clinicians distinguish hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (iCCA), as published in BMC Gastroenterology.  HCC and iCCA are 2 cancers that share overlapping risk factors and clinical signs and symptoms, but strategies to treat either cancer remain different. Hence, it is vital…

Next hm-quiz in CCA Quizzes